TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst

Benzinga Logo Benzinga By Vandana Singh
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst

Bank of America expects Pfizer's 2026 financial outlook to remain flat, with challenges from ongoing patent exclusivity losses and limited pipeline catalysts. The company is focusing on areas like obesity treatments, antibody-drug conjugates, and pneumococcal franchise development.

Insights
AAPL   neutral

Noted as a top portfolio holding without specific performance details


PFE   neutral

Analyst maintains neutral rating due to flat growth expectations, ongoing patent loss challenges through 2029, and limited near-term pipeline catalysts